Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma

Nuclear Medicine Communications

Volumn 31, Issue 11, 2010, Pages 925-930

  Camargo Etchebehere, Elba C S ^a   Romanato, Juliana S ^a   Santos, Allan O ^a   Buzaid, Antonio C ^a   Camargo, Edwaldo E ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

cancer restaging; computed tomography; fluorine 18 fluorodeoxyglucose positron emission tomography computed tomography; malignant melanoma; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET RESTRICTION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; RADIOLOGIST; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77958014106     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833f6137     Document Type: Article

References (18)

1. Kalady MF, White RR, Johnson Jl. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238:528-535.
2. Garbe C, Paul A, Kahler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520-529.
3. Miranda EP, Gertner M, Wall J, Grace E, Kashani-Sabet M, Allen R, Leong SP. Routine imaging of asymptomatic melanoma patients with metastases to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831-837.
4. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664-1671.
5. HolderWD Jr,White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764-771.
6. Stas M, Stroobans S, Dupont P, Gysen M, Hoe LV, Garmyn M, Mortelmans L, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12:479-490.
7. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997; 4:252-258.
8. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178-1187.
9. Akcali C, Zincirkeser S, Erbagcý Z, Akcali A, Halac M, Durak G, et al. Detection of metastases in patients with cutaneous melanoma using FDGPET/ CT. J Int Med Res 2007; 35:547-553.
10. Strobel K, Dummer R, Husarik DB, Pé rez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007; 244:566-574.
11. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
12. Schöder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45 (Suppl 1):72S-81S.
13. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6:325-329.
14. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-Deoxy-2[F-18]Fluoro-D: glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 2005; 23:1-5.
15. Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004; 45:1323-1327.
16. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28:961-965.
17. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002; 9:762-770.
18. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, Larson S. Utility of preoperative [(18)]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006; 13:525-532.